eMedicine Specialties > Ophthalmology > Neurologic Disorders
Multiple Sclerosis: Treatment & Medication
Updated: Jan 26, 2007
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
Treatment
Medical Care
The ONTT provides class I evidence (ie, randomized clinical trial) for recommended treatment of patients with ON. The ONTT results suggest that IV steroids, oral steroids, and placebo all result in recovery of visual function over time. IV steroids hasten the rate of recovery but do not change the final visual outcome. In the ONTT, IV steroids seemed to decrease the incidence of the development of MS over a 2-year period, but this effect was not sustained after year 3.
Although all 3 treatment arms of the study had equal visual outcomes, oral prednisone in conventional doses increased the likelihood for a recurrent episode of ON and is not recommended. Higher doses of oral methylprednisolone have not produced similar increased recurrence rates of ON, but the number of patients in these studies was small.
Newer studies have supported the benefit of using immunomodulatory agents (eg, interferon beta-1) in the reduction of CDMS.
The role for disease modifying agents in the treatment of ON is not to expedite the recovery of optic nerve function, which tends to be good, but rather to impact the risk of future MS. Three studies have addressed the role of interferon therapy for acute monosymptomatic ON and the future development of CDMS.
The first of these studies was the Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study (CHAMPS), in which patients with a single clinically isolated neurologic event (ie, ON, brainstem or cerebellar syndrome, incomplete transverse myelitis) were enrolled into a randomized, placebo-controlled trial if they had 2 or more clinically silent lesions on a cranial MRI. After initial treatment with high-dose IV methylprednisolone, one half of the patients received weekly interferon beta-1a (30 mcg once per week), and one half of the patients received placebo. The primary endpoint was the development of CDMS, and the secondary endpoint was the brain MRI. This study demonstrated a significantly lower rate (44%) of development of CDMS among the treatment group, and a relative reduction of new lesions in the cranial MRIs among patients treated with interferon versus the placebo group.
A second study, the Early Treatment of MS (ETOMS) trial enrolled a similar group of patients, with 4 asymptomatic white matter lesions (or 3 lesions if one enhanced with gadolinium) present on the cranial MRI at presentation. One half of the patients received subcutaneous interferon beta-1a (22 mcg once per week), and one half of the patients received placebo. After 2 years, the odds ratio for the development of CDMS was 0.61 (95% confidence interval [CI] 0.37-0.99; p=0.045) in the treatment group versus the control group. More specifically, 45% of the placebo group developed CDMS after 2 years as compared to 34% of the treatment group. During the treatment study period, the MRI activity and burden of disease measured by MRI were significantly reduced in the treatment group.
In the third and most recent study, the Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT) trial looked at the role of disease modifying therapy in patients with clinically isolated syndromes (either monofocal or multifocal) and at least 2 clinically silent brain MRI lesions. Subjects were randomized to receive 250 mcg of interferon beta-1b subcutaneously on alternate days or placebo until CDMS was diagnosed or the study period of 24 months was reached. Overall, interferon beta-1b delayed the time to diagnosis of MS by clinical and McDonald criteria.
Consultations
Patients with ON, particularly those with an abnormal MRI, should be offered the opportunity to consult with a neurologist regarding the possibility of MS.
Activity
Patients with ON should be cautioned to avoid work and other activities that may require greater visual skills than they possess. Machinery, heavy equipment, sharp instruments, and other visually demanding activities might have to be avoided until they recover sufficient vision, stereovision, color vision, and contrast acuities.
Patients should know that vigorous physical activity, hot baths, and other activities that raise their core body temperature might result in temporary decreases in vision because of the Uhthoff phenomenon.
Medication
Although corticosteroids are known to have multiple short- and long-term adverse effects, in general, a day course of IV methylprednisolone followed by an oral taper over 10-14 days does not produce significant or permanent adverse effects in otherwise healthy young patients.
Corticosteroids
Have both anti-inflammatory (glucocorticoid) and salt-retaining (mineralocorticoid) properties. Glucocorticoids have profound and varied metabolic effects. In addition, these agents modify the body's immune response to diverse stimuli.
Methylprednisolone (Solu-Medrol, Adlone, Medrol)
Decreases inflammation by suppressing migration of polymorphonuclear leukocytes and reversing increased capillary permeability.
Adult
250 mg IV q6h for 3 d
Pediatric
Administer as in adults
Coadministration with digoxin may increase digitalis toxicity secondary to hypokalemia; estrogens may increase levels of methylprednisolone; phenobarbital, phenytoin, and rifampin may decrease levels of methylprednisolone (adjust dose); monitor patients for hypokalemia when taking medication concurrently with diuretics
Documented hypersensitivity; viral infection; peptic ulcer disease; hepatic dysfunction; connective tissue infections; fungal or tubercular skin infections; GI disease
Pregnancy
C - Safety for use during pregnancy has not been established.
Precautions
Adverse effects include hypertension, depression, mania, pseudotumor cerebri, meningitis, psychosis, seizures, pancreatitis, ulcer exacerbation, GI bleeding, peritonitis, toxic megacolon, hyperglycemia, adrenal suppression, Cushing syndrome, growth retardation, hyperlipidemia, cataracts, glaucoma, toxoplasmosis reactivation, TB reactivation, osteoporosis, hyperglycemia, edema, osteonecrosis, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, growth suppression, myopathy, and infections
Prednisone (Deltasone, Orasone, Meticorten)
Should only be used in conjunction with IV methylprednisolone.
Adult
1 mg/kg/d PO for 11 d
Pediatric
Administer as in adults
Coadministration with estrogens may decrease prednisone clearance; concurrent use with digoxin may cause digitalis toxicity secondary to hypokalemia; phenobarbital, phenytoin, and rifampin may increase metabolism of glucocorticoids (consider increasing maintenance dose); monitor for hypokalemia with coadministration of diuretics
Documented hypersensitivity; viral infection; peptic ulcer disease; hepatic dysfunction; connective tissue infections; fungal or tubercular skin infections; GI disease
Pregnancy
B - Usually safe but benefits must outweigh the risks.
Precautions
Caution in mania and depression, GI distress and bleeding, Cushing syndrome, or poor wound healing; abrupt discontinuation of glucocorticoids may cause adrenal crisis; hyperglycemia, edema, osteonecrosis, myopathy, peptic ulcer disease, hypokalemia, osteoporosis, euphoria, psychosis, myasthenia gravis, growth suppression, and infections may occur with glucocorticoid use
Interferons
Are naturally produced proteins with antiviral, antitumor, and immunomodulatory actions. Alpha, beta, and gamma interferons may be given topically, systemically, and intralesionally.
Interferon beta-1a (Avonex, Rebif)
For treatment of relapsing remitting MS. Believed to act via ability to counteract cell surface expression of proinflammatory or proadhesion molecules on immune cells, among other effects. More studies needed to fully understand mechanisms of action. Only differs from interferon beta-1b in that it has amino acid sequence identical to that of natural compound and is glycosylated. Presence of glycosylation may lead to structural stability and presumably to higher biological potency. Interferons act through common receptor that activates Jak/Stat pathway of signal transduction molecules, which, in turn, lead to activation of interferon-responsive genes. Interferon beta may decrease expression of B7-1 (a proinflammatory molecule) on surface of immune cells and increase levels of TGF-beta (anti-inflammatory) in circulation of patients with MS.
Adult
Avonex: 30 mcg IM qwk
Rebif: 44 mcg SC 3 times/wk (at least 48 h between each dose)
Pediatric
Not established
Hematologic abnormalities, including anemia, thrombocytopenia, and development of agranulocytopenia, may occur when administered concomitantly with ACE inhibitors; may increase anticoagulant effects of warfarin; may increase toxicity of zidovudine
Documented hypersensitivity; liver dysfunction; severe leucopenia; thrombocytopenia; lactation
Pregnancy
C - Safety for use during pregnancy has not been established.
Precautions
Caution in preexisting seizure disorder; cases of exacerbation of thyroid dysfunction have been described; caution when using interferon beta-1a in patients with uncontrolled thyroid dysfunction; besides a flulike illness, patients may experience injection-site skin reactions; interferons are abortifacient; data on teratogenicity are limited; extreme caution in patients with severe depression
Antibiotics
Used for suspected bacterial infections.
Tobramycin 0.3% ophthalmic (AK Tob, Tobrex)
Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, which results in a defective bacterial cell membrane. Available as a solution, ointment, and lotion.
Adult
1-2 gtt instilled in the eye q4h while awake for 5 d
Pediatric
<2 years: Not established
>2 years: Administer as in adults
Effects decrease when used concurrently with gentamicin
Documented hypersensitivity; mycobacterial, viral, and fungal infections of the eye; steroid combinations after uncomplicated removal of a foreign body from cornea
Pregnancy
C - Safety for use during pregnancy has not been established.
Precautions
Do not use in deep-seated ocular infections or in those that may become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms
More on Multiple Sclerosis |
| Overview: Multiple Sclerosis |
| Differential Diagnoses & Workup: Multiple Sclerosis |
 Treatment & Medication: Multiple Sclerosis |
| Follow-up: Multiple Sclerosis |
| References |
| « Previous Page | Next Page » |
References
Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med. Feb 27 1992;326(9):581-8. [Medline].
Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol. Apr 2002;51(4):481-90. [Medline].
Beck RW, Gal RL, Bhatti MT, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol. Jan 2004;137(1):77-83. [Medline].
Beck RW, Trobe JD, Moke PS, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol. Jul 2003;121(7):944-9. [Medline].
Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain. Apr 2004;127(Pt 4):844-50. [Medline].
Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. Jun 1980;103(2):281-300. [Medline].
Dunker S, Wiegand W. Prognostic value of magnetic resonance imaging in monosymptomatic optic neuritis. Ophthalmology. Nov 1996;103(11):1768-73. [Medline].
Earl CJ. Some aspects of optic atrophy. Trans Ophthalmol Soc U K. 1964;84:215-26. [Medline].
Fleishman JA, Beck RW, Linares OA, Klein JW. Deficits in visual function after resolution of optic neuritis. Ophthalmology. Aug 1987;94(8):1029-35. [Medline].
Frohman EM, O'Suilleabhain P, Dewey RB Jr, et al. A new measure of dysconjugacy in INO: the first-pass amplitude. J Neurol Sci. Jun 15 2003;210(1-2):65-71. [Medline].
Galetta SL. The controlled high risk Avonex multiple sclerosis trial (CHAMPS Study). J Neuroophthalmol. Dec 2001;21(4):292-5. [Medline].
Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. Jan 22 2002;58(2):169-78. [Medline].
Haegert DG, Marrosu MG. Genetic susceptibility to multiple sclerosis. Ann Neurol. Dec 1994;36 Suppl 2:S204-10. [Medline].
Hely MA, McManis PG, Doran TJ, et al. Acute optic neuritis: a prospective study of risk factors for multiple sclerosis. J Neurol Neurosurg Psychiatry. Oct 1986;49(10):1125-30. [Medline].
Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. Sep 28 2000;343(13):898-904. [Medline].
Jacobs LD, Kaba SE, Miller CM, et al. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol. Mar 1997;41(3):392-8. [Medline].
Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. Dec 11-17 2004;364(9451):2106-12. [Medline].
Liu Z, Pelfrey CM, Cotleur A, et al. Immunomodulatory effects of interferon beta-1a in multiple sclerosis. J Neuroimmunol. Jan 1 2001;112(1-2):153-62. [Medline].
McDonald WI. Acute optic neuritis. Br J Hosp Med. Jul 1977;18(1):42-8. [Medline].
Milea D, Napolitano M, Dechy H, et al. Complete bilateral horizontal gaze paralysis disclosing multiple sclerosis. J Neurol Neurosurg Psychiatry. Feb 2001;70(2):252-5. [Medline].
Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. May 2005;4(5):281-8. [Medline].
Miller DH, Newton MR, van der Poel JC, et al. Magnetic resonance imaging of the optic nerve in optic neuritis. Neurology. Feb 1988;38(2):175-9. [Medline].
Miller NR, Newman NJ. Optic neuritis. In: The Essentials: Walsh and Hoyt's Clinical Neuro-Ophthalmology. 5th ed. Lippincott Williams & Wilkins;1999: 196-220.
Miller NR. Optic neuritis. In: Walsh & Hoyt's Clinical Neuro-Ophthalmology. 4th ed. Lippincott Williams & Wilkins;1982: 227-48.
Noseworthy JH. Management of multiple sclerosis: current trials and future options. Curr Opin Neurol. Jun 2003;16(3):289-97. [Medline].
Optic Neuritis Study Group. The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol. Dec 1991;109(12):1673-8. [Medline].
Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Optic Neuritis Study Group. Neurology. Nov 1997;49(5):1404-13. [Medline].
PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. Nov 7 1998;352(9139):1498-504. [Medline].
PRISMS Study Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. Jun 26 2001;56(12):1628-36. [Medline].
Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. Nov 26 2002;59(10):1496-506. [Medline].
Percy AK, Nobrega FT, Kurland LT. Optic neuritis and multiple sclerosis. An epidemiologic study. Arch Ophthalmol. Feb 1972;87(2):135-9. [Medline].
Pittock SJ, McClelland RL, Mayr WT, et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann Neurol. Aug 2004;56(2):303-6. [Medline].
Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. Dec 2005;58(6):840-6. [Medline].
Sandberg-Wollheim M, Bynke H, Cronqvist S, et al. A long-term prospective study of optic neuritis: evaluation of risk factors. Ann Neurol. Apr 1990;27(4):386-93. [Medline].
Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology. Mar 1998;50(3):708-14. [Medline].
Weinstock-Guttman B, Baier M, Stockton R, et al. Pattern reversal visual evoked potentials as a measure of visual pathway pathology in multiple sclerosis. Mult Scler. Oct 2003;9(5):529-34. [Medline].
Wray SH. Optic neuritis. In: Albert DM, Jakobiec FA, eds. Principles and Practice of Ophthalmology. Vol 4. WB Saunders;1994: 2539-68.
Further Reading
Keywords
MS, neurologic disorder, optic neuritis, ON, optic nerve, nystagmus, internuclear ophthalmoplegia, INO
